Aclasta IV Infusion 5 mg/100 ml

Aclasta IV Infusion: Comprehensive Drug Information

Aclasta IV Infusion (Zoledronic Acid) is a bisphosphonate preparation manufactured by SANDOZ (A Novartis Division). Priced at ৳38,190.00 per 5 mg/100 ml unit, it treats osteoporosis, Paget’s disease, and glucocorticoid-induced bone loss. Administered via IV Infusion, it requires annual or biennial dosing under medical supervision.

This medication inhibits osteoclast-mediated bone resorption, stabilizing bone mineral density. Patients receive a single 5 mg dose over 15 minutes. Storage below 30°C is crucial to maintain efficacy. Common side effects include fever (pyrexia), muscle pain, and headache. Severe renal impairment or hypocalcemia requires caution.

Key indications:

• Postmenopausal osteoporosis treatment/prevention
• Male osteoporosis therapy
• Paget’s disease management
• Glucocorticoid-induced bone loss

Patients must supplement with 1,200 mg calcium and 800-1000 IU vitamin D daily. Drug interactions with aminoglycosides or diuretics may worsen hypocalcemia. Regular renal monitoring is advised during treatment. Contraindicated in pregnancy and lactation due to fetal risks.

5 mg annual IV infusion over minimum 15 minutes. Contraindicated in renal impairment (CrCl <35 ml/min). Pre-dose renal function monitoring mandatory. Re-evaluate osteoporosis treatment after 3-5 years. Paget's disease requires co-administration of 1500 mg calcium and 800 IU vitamin D daily.

The most common adverse reactions (greater than 10%) were pyrexia, myalgia, headache, arthralgia, pain in extremity. Other important adverse reactions were flu-like illness, nausea, vomiting, diarrhea, and eye inflammation

Pregnancy category D: Positive evidence of fetal risk. Contraindicated in lactation. Women of childbearing potential must use effective contraception.

Monitor serum calcium and vitamin D levels regularly. Dental examinations mandatory pre-treatment. Never administer IV infusion faster than 15 minutes. Evaluate thigh pain with X-ray promptly.

Pediatric use prohibited. Geriatric patients require renal monitoring. No dose adjustment needed for hepatic impairment. Renal impairment (CrCl ≥35 ml/min) needs no modification.

Patients who have received doses higher than those recommended should be carefully monitored. Over dosage may cause clinically significant renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively. Single doses of Aclasta should not exceed 5 mg and the duration of the intravenous infusion should be no less than 15 minutes.